16+
DOI: 10.18413/2313-8955-2015-1-4-19-24

PHARMACOLOGICAL CORRECTION OF IMMUNE DISORDERS IN PATIENTS WITH CHRONIC HEART FAILURE AND ISCHEMIC HEART DISEASE

Currently, there are few data on the effect of cardiovascular drugs on the immune status of patients with heart failure (HF). This paper provides information on the impact of ß-adrenergic blocking agent (BAB), angiotensin-converting enzyme inhibitors (ACEI) on the maintenance of markers of immune inflammation in the blood, as well as on inhibition of synthesis of tumor necrosis factor-α (TNF-α) and on blocking of interaction between TNF-α and membrane receptors.

Number of views: 5534 (view statistics)
Количество скачиваний: 6991
Full text (HTML)Full text (PDF)To articles list
  • User comments
  • Reference lists

While nobody left any comments to this publication.
You can be first.

Leave comment: